Omada Health, Inc. (OMDA) AI Stock Analysis
OMDA AI stock analysis summary
AI ResearchOmada Health, Inc. (OMDA) provides virtual care programs across cardiometabolic health, physical therapy, and behavioral health. The company grew revenue at a 42.9% 3-year CAGR from FY2022 to FY2025, reaching $260.2M while turning free cash flow positive at $16.9M. For the trailing twelve months ended June 30, 2026, revenue stood at $309.8M with an operating margin of 4.0%.
- Market cap
- $1.08B
- Revenue (TTM)
- $309.8M
- P/E
- 73.5x fwd 137.0x
- 1Y return
- -29.3% S&P 500 16.8%
- Avg. target
- $28.42 61.2% vs last close
Bull case
- Annual revenue grew 53.2% in FY2025 to $260.2M, supported by a 42.9% 3-year revenue CAGR from FY2022.
- Free cash flow turned positive at $16.9M in FY2025, alongside gross margin expansion to 65.7%.
- Wall Street analysts have a mean price target of $28.42, which sits 61.2% above the last close of $17.63.
Bear case
- The stock trades at elevated valuation multiples, including a forward P/E of 137.0x and an EV to EBITDA ratio of 101.3x.
- The company posted a 1-year return of -29.3%, underperforming the S&P 500 return of 16.8% over the same period.
- Short interest remains notable, with short percent of float recorded at 12.4%.
What Omada Health does
Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension, as well as a physical therapy program targeting musculoskeletal conditions. In addition, it provides support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program, weight management programs, and various behavioral health support programs. Omada delivers virtual care to employers, health plans and systems, and pharmacy benefits managers through direct sales and channel partners.
Growth and profitability
Omada Health increased annual revenue from $89.2M in FY2022 to $260.2M in FY2025, reflecting a 3-year CAGR of 42.9% and FY2025 growth of 53.2%. Gross margin steadily widened from 48.0% in FY2022 to 65.7% in FY2025. Operating margin improved from -81.1% in FY2022 to -4.6% in FY2025, while net losses narrowed from -$72.5M to -$12.8M. For the trailing twelve months ended June 30, 2026, revenue reached $309.8M, net profit margin was 1.4%, operating margin was 4.0%, and quarterly revenue growth year-over-year reached 43.1%.
Balance sheet and cash flow
As of June 30, 2026, Omada Health held $221.7M in cash and short-term investments, with total assets of $328.2M and shareholders' equity of $252.7M. The company maintained a current ratio of 3.91. In FY2025, operating cash flow reached $18.3M and free cash flow turned positive to $16.9M. Capital expenditures for FY2025 totaled $1.3M, while research and development expenses were $40.7M.
Valuation and performance
Omada Health trades at a trailing P/E of 73.5x and a forward P/E of 137.0x, compared to medians of 24.6x and 17.3x, respectively, for its US-listed Healthcare peers. Its enterprise value of $1.07B reflects an EV to EBITDA multiple of 101.3x versus the peer median of 12.0x, while its price-to-sales multiple of 3.5x sits below the peer median of 4.1x. Over the past year, OMDA declined 29.3%, while the S&P 500 (SPY) gained 16.8%.
What analysts expect
Wall Street analysts covering Omada Health hold 5 Strong Buy, 5 Buy, and 2 Hold recommendations, with no Sell or Strong Sell ratings. The mean price target is $28.42, representing 61.2% above the last close of $17.63 on October 16, 2026. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $338.7M and EPS of $0.44. Omada has beat EPS estimates in each of the last 4 quarters, with its next earnings date scheduled for November 5, 2026.
Key risks and what to watch
- Operating margin on a trailing twelve-month basis is thin at 4.0%, leaving limited buffer against unexpected cost increases.
- Short percent of float sits at 12.4%, reflecting significant skepticism in the market.
- The stock dropped 29.3% over the trailing 12 months, trading well below its 52-week high of $26.91.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this OMDA AI stock analysis
This page is an AI-written research summary of Omada Health, Inc. (OMDA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: OMDA income statement, OMDA balance sheet, OMDA key metrics, OMDA analyst forecast, OMDA chart. See the OMDA stock overview for the latest quote and news.
OMDA AI stock analysis FAQ
When does Omada Health report its next earnings?
Omada Health is scheduled to report its next earnings on November 5, 2026. The company has beaten EPS expectations in each of the last 4 quarters.
What is the consensus analyst target price for OMDA?
The mean analyst price target is $28.42, which represents a 61.2% premium over the October 16, 2026 closing price of $17.63.
Does Omada Health pay a dividend?
No, Omada Health does not pay a dividend. The company directs capital toward business operations, including $40.7M in R&D spending in FY2025.
How fast is Omada Health growing its revenue?
Omada Health delivered a 3-year revenue CAGR of 42.9% between FY2022 and FY2025. In the latest quarter ended June 30, 2026, quarterly revenue grew 43.1% year-over-year.